A fundamental shift in the design of clinical trials for psychotic disorders is desirable and feasible. Priority should be placed on evaluation of the efficacy of interventions targeting different phases of illness.
A range of traditional therapeutic approaches needs to be augmented by an increased emphasis on the potential benefits of informational, e-health, behavioural and neuroprotective strategies.
A new national clinical trials platform, based on headspace, the National Youth Mental Health Foundation, is outlined. It provides the opportunity for conducting large multisite clinical trials in young people with emerging major mental disorders.
- 1. Häfner H, Maurer K, Trendler G, et al. Schizophrenia and depression: challenging the paradigm of two separate diseases — a controlled study of schizophrenia, depression and healthy controls. Schizophr Res 2005; 77: 11-24.
- 2. McGorry PD, Purcell R, Hickie IB, et al. Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust 2007; 187 (7 Suppl): S40-S42. <MJA full text>
- 3. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004; 67: 131-142.
- 4. Yung AR, McGorry PD, McFarlane CA, et al. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996; 22: 283-303.
- 5. Edwards J, McGorry PD. Implementing early intervention in psychosis. A guide to establishing early psychosis services. London: Martin Dunitz, 2002.
- 6. Andrews G, Sanderson K, Corry J, et al. Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry 2003; 183: 427-435.
- 7. Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003; 12: 22-33.
- 8. Insel TR. Beyond efficacy: the STAR*D trial. Am J Psychiatry 2006; 163: 5-7.
- 9. Berger GE, Wood S, McGorry PD. Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacol Bull 2003; 37: 79-101.
- 10. Yao JK, Reddy RD. Membrane pathology in schizophrenia: implication for arachidonic acid signaling. ScientificWorldJournal 2002; 2: 1922-1936.
- 11. Phillips LJ, McGorry PD, Garner B, et al. Stress, the hippocampus and the hypothalamic–pituitary–adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry 2006; 40: 725-741.
- 12. Corcoran C, Walker E, Huot R, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull 2003; 29: 671-692.
- 13. Ng F, Berk M, Dean O, Bush A. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11: 851-876.
- 14. Berger GE, Proffitt TM, McConchie M, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry 2007; 68: 1867-1875.
- 15. Amminger GP, Schäfer MR, Papageorgiou K, et al. Relationship between reduced erythrocyte membrane fatty acids and transition to psychosis in ultra high risk individuals [abstract]. Schizophr Res 2008; 98 Suppl 1: 108.
- 16. Berger GE, Wood SJ, Pantelis C, et al. Implications of lipid biology for the pathogenesis of schizophrenia. Aust N Z J Psychiatry 2002; 36: 355-366.
- 17. Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis 2007; 6: 21.
- 18. Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev 2005; 45: 1-28.
- 19. Bachmann RF, Schloesser RJ, Gould TD, Manji HK. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 2005; 32: 173-202.
- 20. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999; 4: 117-128.
- 21. Moore GJ, Bebchuk JM, Wilds IB, et al. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241-1242.
- 22. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008; 105: 2052-2057.
- 23. Berger G, Dell’Olio M, Amminger P, et al. Neuroprotection in emerging psychotic disorders. Early Interv Psychiatry 2007; 1: 114-127.
- 24. Velakoulis D, Wood SJ, Wong MTH, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006; 63: 139-149.
- 25. Phillips LJ, McGorry PD, Garner B, et al. Stress, the hippocampus and the hypothalamic–pituitary–adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry 2006; 40: 725-741.
- 26. Thompson KN, Phillips LJ, Komesaroff P, et al. Stress and HPA-axis functioning in young people at ultra high risk for psychosis. J Psychiatr Res 2007; 41: 561-569.
- 27. Thompson KN, Berger G, Phillips LJ, et al. HPA axis functioning associated with transition to psychosis: combined DEX/CRH test. J Psychiatr Res 2007; 41: 446-450.
- 28. Dupin N, Mailliet F, Rocher C, et al. Common efficacy of psychotropic drugs in restoring stress-induced impairment of prefrontal plasticity. Neurotox Res 2006; 10: 193-198.
- 29. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia — a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64: 361-368.
- 30. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder — a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468-475.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.